| dbpprop:abstract
|
- Parecoxib is a water soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib and rofecoxib. As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac is used in the United States. However, unlike ketorolac, parecoxib has no effect on platelet function and therefore does not promote bleeding during or after surgery. In addition, ketorolac has a much higher gastrointestinal toxicity profile compared to most other nonsteroidal antiinflammatory drugs including ibuprofen and naprosyn. However, in the United States ketorolac is the only injectable NSAID, although it is banned in many European countries due to concerns about surgical bleeding and stomach ulcers after surgery. In 2005, the U.S. Food and Drug Administration (FDA) issued a letter of non-approval for parecoxib in the United States. No reasons were ever documented publicly for the non-approval, although one study noted increased occurrences of heart attacks following cardiac bypass surgery compared to placebo when high doses of parecoxib were used to control pain after surgery. It is also important to remember that rare but severe allergic reactions (Stevens-Johnson Syndrome, Lyell Syndrome) have been described with valdecoxib, the molecule in which parecoxib is converted . The drug is not approved for use after cardiac surgery in Europe. Ketorolac, still banned in much of Europe, is therefore the only option in the United States, and it is not clear whether parecoxib will be resubmitted to the FDA in the future.
- Parecoxib ist ein Arzneistoff aus der Gruppe der selektiven COX-2-Hemmer (Cyclooxygenase-2-Hemmer) und wird von der Firma Pfizer unter dem Handelsnamen Dynastat vertrieben. Parecoxib ist wegen Sicherheitsbedenken in den USA nicht zugelassen und in der Schweiz vom Markt genommen worden.
- Parecoxibul este un prodrug al valdecoxibului, fiind ca şi acesta un inhibitor din clasa AINS, a coxibilor, cu o potenţă analgezică de circa 20 ori mai mare decît a ketorolacului. Se administrează numai pe cale injectabilă. În studiile efectuate parecoxibul, la concentraţii de 20 40 mg, a demonstrat efecte analgezice mai puternice versus placebo sau morfina 4 mg şi similară cu 300 mg ketorolac administrat intravenos. Parecoxibul administrat a determinat eroziuni gastrointestinale mai pronunţate comparativ cu ketorolac. Contraindicaţii: bronhospasm in antecedente, polipoză nazală, hipersensibilitate, insuficienţă hepatică severă, insuficienţă cardiacă congestivă, ulcer gastro-duodenal, sarcină. Efecte adverse: edeme periferice, tulburări ale tensiunii arteriale, dispepsie, flatulenţă, agitaţie, insomnie, faringită, prurit.
|
| rdfs:comment
|
- Parecoxib is a water soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib and rofecoxib. As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac is used in the United States.
- Parecoxib ist ein Arzneistoff aus der Gruppe der selektiven COX-2-Hemmer (Cyclooxygenase-2-Hemmer) und wird von der Firma Pfizer unter dem Handelsnamen Dynastat vertrieben. Parecoxib ist wegen Sicherheitsbedenken in den USA nicht zugelassen und in der Schweiz vom Markt genommen worden.
- Parecoxibul este un prodrug al valdecoxibului, fiind ca şi acesta un inhibitor din clasa AINS, a coxibilor, cu o potenţă analgezică de circa 20 ori mai mare decît a ketorolacului. Se administrează numai pe cale injectabilă. În studiile efectuate parecoxibul, la concentraţii de 20 40 mg, a demonstrat efecte analgezice mai puternice versus placebo sau morfina 4 mg şi similară cu 300 mg ketorolac administrat intravenos.
|
![[RDF Data]](/statics/sw-cube.png)
